SCHEMBL8517219

SCHEMBL8517219

CCCCc1cc(OCc2ccccc2)c(C(=O)O)c2ncnn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 2/20 0.47
FOLH1 Q04609 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
EGLN1 Q9GZT9 2/20 0.37
BRD4 O60885 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
SRD5A2 P31213 2/20 0.36
PTGER4 P35408 1/20 0.36
PTGER3 P43115 1/20 0.36
PTGER2 P43116 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15744035 0.93 PTGER1 (0.44) PTGER1EGLN1BRD4FFAR4PTGES
SCHEMBL8517633 0.88 PTGER1 (0.41) PTGER1EGLN1FFAR4PTGESALOX5
SCHEMBL8517177 0.84 PPARA (0.39) MEN1KMT2AEGLN1KDM5AKDM5B
SCHEMBL8520679 0.79 EGLN2 (0.43) PTGER1FOLH1MEN1KMT2AEGLN1
SCHEMBL8522878 0.78 PTPN1 (0.41) EGLN1KDM5AKDM5BPTGES
SCHEMBL30599268 0.77 NR4A2 (0.40) FOLH1MEN1KMT2AKDM5AKDM5B
SCHEMBL12750387 0.75 FOLH1 (0.37) PTGER1FOLH1MEN1KMT2AEGLN1
SCHEMBL8520855 0.73 ALKBH1 (0.40) PTGER1FOLH1MEN1KMT2AEGLN1
SCHEMBL12750427 0.73 PPIA (0.43) MEN1KMT2ANPC1HPGDRAB9A
SCHEMBL30812491 0.72 EGLN1 (0.49) EGLN1KDM5AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885FOLH1 1036/4885MRGPRX4 2819/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885FOLH1 1036/4885MRGPRX4 2819/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885FOLH1 1036/4885MRGPRX4 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.